OCUL

NASDAQ · Pharmaceuticals

Ocular Therapeutix Inc

Small-Cap Stocks Stocks Under $10 Pharmaceutical Stocks Healthcare Stocks

$7.14

+0.32 (+4.69%)

As of Nov 7, 1:42 AM ET ·

OCUL News1 articles

Oculis Shares Plunge as Eye Drop Fails Key Trial Goal

Oculis shares tumbled 23.4% after two Phase 3 trials of OCS-01 eye drops for diabetic macular edema failed to meet the main vision goal. The company will not pursue U.S. approval for this indication.